Compare Freshworks Inc (FRSH) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Summit Therapeutics Inc — how do they compare? Freshworks Inc trades at $10.75 (market cap $2.93B), while Summit Therapeutics Inc trades at $14.36 (market cap $11.70B). The key difference: Summit Therapeutics Inc is far larger — about 4× Freshworks Inc's market cap, and Freshworks Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| FRSH | SMMT | |
|---|---|---|
Market Cap | $2.93B | $11.70B |
Sector | Technology | Health |
52-Week High | $14.77 | $29.32 |
52-Week Low | $6.88 | $13.05 |
Enterprise Value | $2.19B | $11.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $10.47, down 3.32% on the day, with a bullish technical signal from moving averages. The company shows a strong fundamental turnaround, achieving profitability in 2025 with a net income margin of 20.69% and robust revenue growth from $498M in 2022 to $839M in 2025. Recent news highlights a strategic pivot to its employee experience (EX) business and new AI product launches, with the Q2 2026 earnings report scheduled for August 4, 2026.
The outlook is positive, supported by a profitable growth trajectory, a 50% analyst buy rating, and a significant valuation discount to software peers. Key risks include execution of the EX pivot, competitive pressures in SaaS, and the need to sustain high gross margins. The stock offers opportunity as a value play with accelerating fundamentals, but faces typical growth stock volatility.
Summit Therapeutics (SMMT) trades at $14.51, down 6.21% today, with a bearish technical outlook despite positive clinical trial results for its lung cancer drug ivonescimab. The company reported a net loss of $1.08 billion in 2025, with negative ROE and ROA, but maintains strong analyst support with 14 buy ratings and a $15.57 consensus price target. Recent developments include the $105 million divestiture of ridinilazole to Biossil and upcoming Q2 2026 earnings.
SMMT presents a high-risk, binary investment case centered on ivonescimab's commercial potential. While analyst sentiment is bullish and recent trial data is promising, the company's significant losses, cash burn, and single-asset focus pose substantial risks. The stock's volatility and concentrated ownership create potential for sharp moves around clinical and regulatory catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
